Skip to main content
. 2018 Sep 10;2018(9):CD007287. doi: 10.1002/14651858.CD007287.pub4

Ströhlein 2009.

Methods Uncontrolled phase I study
Participants 9 patients with progressive peritoneal carcinomatosis (ovarian cancer n = 2)
Interventions Intraperitoneal trifunctional antibody targeting EpCAM (n = 1) or Her‐2/Neu (n = 1)
Outcomes Survival: not reported separately for ovarian cancer patients
Tumour responses
Immune responses: cellular, humoral (HAMA)
Adverse events
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence generation (selection bias) High risk Uncontrolled trial
Allocation concealment (selection bias) High risk Uncontrolled trial
Blinding of participants and personnel (performance bias) 
 All outcomes Unclear risk Information insufficient to permit judgement of ‘low risk’ or ‘high risk’
Blinding of outcome assessment (detection bias) 
 All outcomes Unclear risk Information insufficient to permit judgement of ‘low risk’ or ‘high risk’
Incomplete outcome data (attrition bias) 
 All outcomes Unclear risk Information insufficient to permit judgement of ‘low risk’ or ‘high risk’
Selective reporting (reporting bias) Unclear risk Information insufficient to permit judgement of ‘low risk’ or ‘high risk’
Other bias Unclear risk Information insufficient to permit judgement of ‘low risk’ or ‘high risk’